Voyager Therapeutics, Inc.
General ticker "VYGR" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $242.7M (TTM average)
Voyager Therapeutics, Inc. follows the US Stock Market performance with the rate: 46.9%.
Estimated limits based on current volatility of 2.6%: low 3.88$, high 4.09$
Factors to consider:
- Total employees count: 172 (+6.2%) as of 2024
- Top business risk factors: Lack of profitability, Market competition, Regulatory and compliance, Labor/talent shortage/retention, Manufacturing risks
- Price in estimated range
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [3.28$, 7.51$]
- 2026-12-31 to 2027-12-31 estimated range: [3.49$, 7.81$]
Financial Metrics affecting the VYGR estimates:
- Positive: with PPE of -2.0 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -55.54 <= 0.07
- Positive: Investing cash flow per share per price, % of 52.59 > -0.65
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Negative: negative Net income
- Negative: Inventory ratio change, % of 19.58 > 0.80
Short-term VYGR quotes
Long-term VYGR plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $250.01MM | $80.00MM | $40.37MM |
| Operating Expenses | $127.99MM | $163.29MM | $172.22MM |
| Operating Income | $122.01MM | $-83.29MM | $-131.84MM |
| Non-Operating Income | $11.72MM | $18.95MM | $12.27MM |
| R&D Expense | $92.17MM | $127.37MM | $134.67MM |
| Income(Loss) | $133.74MM | $-64.34MM | $-119.58MM |
| Taxes | $1.41MM | $0.67MM | $0.14MM |
| Profit(Loss)* | $132.33MM | $-65.00MM | $-119.72MM |
| Stockholders Equity | $236.32MM | $299.76MM | $196.08MM |
| Assets | $351.28MM | $393.05MM | $252.28MM |
| Operating Cash Flow | $77.92MM | $-15.31MM | $-132.47MM |
| Capital expenditure | $3.26MM | $3.52MM | $2.60MM |
| Investing Cash Flow | $-141.64MM | $-94.86MM | $125.45MM |
| Financing Cash Flow | $33.65MM | $114.02MM | $0.82MM |
| Earnings Per Share** | $3.08 | $-1.13 | $-2.04 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.